Predictive Oncology (POAI) Corporate Media Kit

PredictiveOncology (NASDAQ: POAI) is focused on the use of data and artificial intelligence (“AI”) for precisionmedicine and the development of new therapies. With several tools that support its mission to bring precision medicine to cancer, the company intends to accelerate the path to more effective treatments and improved patient outcomes. Predictive Oncology, together with its subsidiaries, owns an inno- vative asset portfolio that includes: Next-Gen Platforms – In-house platforms including a clinically val- idated “smart” patient-derived (PDx) tumor profiling, as well as one that leverages bioinformatics and artificial intelligence (“AI”) to build predictive models of tumor drug response Historical Database - Historical data on the drug-response profiles of over 150,000 patient tumors, together with access to patient out- come data